In comparison to type 2 diabetes (T2D), individuals with LADA have lower insulin secretion and a faster progression to insulin dependency; furthermore, islet autoantibodies are biomarkers of autoimmune beta-cell destruction that distinguish LADA from T2D1. The gene discussed is INS; the disease is type 2 diabetes mellitus.